Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Douglas L. Arnold et al.|The Lancet Neurology|2021Cited by 192
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damageMassimo Filippi, Katrin Gross‐Paju, Maria A. Rocca et al.|Journal of Neurology Neurosurgery & Psychiatry|2013Cited by 114
Teriflunomide added to interferon-β in relapsing multiple sclerosisM. S. Freedman, K. Ton, Jerry S. Wolinsky et al.|Neurology|2012Cited by 78
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Liesbeth Van Hijfte et al.|JAMA Neurology|2023Cited by 62
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data networkAlessio Signori, Helmut Butzkueven, Johannes Lorscheider et al.|Journal of Neurology Neurosurgery & Psychiatry|2022Cited by 17